A cost-effectiveness analysis in a Norwegian setting: Introducing genotyping to patients with ACS treated with PCI before prescribing antiplatelet therapy

dc.contributor.author	Politi, Angeliki Louiza
dc.date.accessioned	2021-03-19T15:05:49Z
dc.date.available	2021-03-19T15:05:49Z
dc.date.issued	2021
dc.description	Master in Health Economics and Pharmacoeconomics (UPF Barcelona School of Management) Curs 2018-2021	ca
dc.description	Mentor: Carlos Crespo
dc.description.abstract	The purpose of this study is to conclude as to whether it is cost-effective to introduce genotyping in the Norwegian clinical practice in the case of acute coronary syndrome, as a guide of pharmacotherapy decision making after a percutaneous coronary intervention.	ca
dc.format.mimetype	application/pdf	*
dc.identifier.uri	http://hdl.handle.net/10230/46867
dc.language	eng
dc.language.iso	eng	ca
dc.rights	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License	ca
dc.rights.accessRights	info:eu-repo/semantics/openAccess	ca
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/	ca
dc.subject.other	Treball de fi de màster – Curs 2020-2021	ca
dc.subject.other	Clopidogrel	ca
dc.subject.other	Ticagrelor	ca
dc.subject.other	Percuntaneous coronary intervention	ca
dc.subject.other	economic evaluation	ca
dc.subject.other	cost.effectiveness	ca
dc.subject.other	CYP	ca
dc.subject.other	antiplatelets	ca
dc.title	A cost-effectiveness analysis in a Norwegian setting: Introducing genotyping to patients with ACS treated with PCI before prescribing antiplatelet therapy	ca
dc.type	info:eu-repo/semantics/masterThesis	ca

Now showing 1 - 1 of 1